Zilda 50mg Tablet contains Vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. By selectively inhibiting the DPP-4 enzyme, Vildagliptin enhances the levels of incretin hormones, which in turn increase insulin secretion and decrease glucagon release in a glucose-dependent manner, thereby improving glycemic control. Zilda 50mg is prescribed as an adjunct to diet and exercise to achieve better blood glucose regulation in adults inadequately controlled by lifestyle modifications alone. It may be used as monotherapy or in combination with other antidiabetic agents such as metformin or sulfonylureas. The medication is generally well tolerated, with a low risk of hypoglycemia due to its glucose-dependent mechanism of action. Common adverse effects may include headache, dizziness, and gastrointestinal disturbances, although serious side effects are rare. Caution is advised in patients with renal or hepatic impairment, and dose adjustments may be necessary. Regular monitoring of blood glucose and renal function is recommended during therapy. Zilda 50mg Tablet should be used under medical supervision, with adherence to prescribed dosage and lifestyle interventions to optimize therapeutic outcomes in type 2 diabetes management.